GLP-1 and obesity drug coverage expansion · Thesis · Arbora ↑

CVS Caremark's decision to cover Eli Lilly's full obesity drug portfolio — including the newly approved oral therapy Foundayo — marks a major commercial inflection point for GLP-1 drugs, dramatically expanding the addressable patient population. Novo Nordisk is simultaneously partnering with NOVI Health to broaden access to physician-led weight-loss programs. With late-stage trial results continuing to impress and pharmacy benefit managers now actively expanding formulary coverage, LLY and NVO are positioned for sustained revenue acceleration in the obesity and metabolic disease space.

Core thesis

CVS Caremark's full formulary coverage of Eli Lilly's obesity portfolio — including the first oral GLP-1 therapy Foundayo — combined with Novo Nordisk's expanding physician-led access programs, creates a structural demand inflection that should drive sustained revenue acceleration for both LLY and NVO.

Causal chain

Formulary inclusion → Patient access → Volume acceleration → Revenue growth

  1. PBM gatekeeping removed: CVS Caremark, one of the largest pharmacy benefit managers in the U.S., has added Lilly's full obesity portfolio — including Zepbound and the newly approved oral Foundayo — to its covered formulary. Because PBMs effectively determine which drugs tens of millions of insured patients can access at manageable out-of-pocket cost, this decision is not merely symbolic; it directly unlocks a previously price-excluded patient cohort. Without formulary coverage, list-price GLP-1 drugs were financially inaccessible to a large share of commercially insured patients, suppressing real-world demand well below clinical demand.

  2. Oral formulation removes the injection barrier: Foundayo's oral delivery addresses a distinct and sizable segment of patients who declined injectable GLP-1 therapies due to needle aversion or lifestyle friction. With PBM coverage now layered on top of the oral format, two compounding adoption barriers — cost and administration — are simultaneously lowered, meaningfully widening the addressable patient population beyond what injectable coverage alone would achieve.

  3. Physician-led programs amplify NVO's reach: Novo Nordisk's partnership with NOVI Health to expand structured, physician-supervised weight-loss programs broadens the clinical infrastructure through which NVO's therapies are prescribed and managed. This is important because GLP-1 adoption is partly gated by physician engagement and program availability; structured care settings improve adherence and outcomes, which in turn supports continued prescribing and reduces discontinuation — a persistent drag on GLP-1 revenue durability.

  4. Positive late-stage trial data sustains clinical credibility: Continued strong Phase 3 results reinforce prescriber confidence and support potential label expansions into adjacent metabolic and cardiovascular indications. Broader approved indications would further justify formulary inclusion across additional therapeutic categories, compounding the commercial opportunity beyond obesity alone.

  5. Competitive reinforcement, not pure rivalry: With both LLY and NVO expanding access through complementary channels — PBM coverage and clinical program infrastructure respectively — the overall GLP-1 market grows faster than either company could drive alone, validating the category to payers and providers and creating a rising-tide dynamic that benefits both incumbents.

Key drivers

  • CVS Caremark formulary win for LLY is a high-confidence, high-signal commercial catalyst (signal 0.95, confidence 0.92) that directly converts latent clinical demand into covered prescriptions at scale
  • First oral GLP-1 approval (Foundayo) differentiates LLY's portfolio and opens a new patient segment, reducing dependence on injectable uptake alone
  • NVO's NOVI Health partnership extends physician-led program infrastructure, improving patient identification, initiation, and adherence — key levers for long-term revenue durability
  • Late-stage trial momentum continues to validate the therapeutic class, supporting both label expansion and payer willingness to cover broader indications
  • Secular tailwind: Obesity affects a large and growing share of the global population; even modest penetration gains translate into substantial incremental revenue given the chronic, long-duration nature of GLP-1 treatment
  • PBM precedent effect: CVS Caremark's decision may pressure other major PBMs (Express Scripts, OptumRx) to follow suit to remain competitive in employer and health plan negotiations, potentially triggering a cascade of additional formulary inclusions

Risks and counter-case

  • Pricing pressure from formulary negotiations: PBM coverage wins typically come with rebate and net-price concessions; the volume gain may be partially offset by lower realized revenue per unit, compressing margins more than headline growth suggests
  • Discontinuation and adherence risk: GLP-1 therapies have historically shown high real-world discontinuation rates due to side effects (nausea, GI intolerance) and cost burden; if patients covered under new formularies discontinue at elevated rates, the revenue durability thesis weakens
  • Competitive pipeline erosion: A growing number of pharma and biotech companies are developing next-generation obesity therapies (oral small molecules, combination agents); accelerated competition could erode LLY's and NVO's pricing power and market share faster than expected
  • Regulatory and safety risk: Any post-market safety signal — particularly for the novel oral formulation Foundayo — could trigger label restrictions, prescriber caution, or formulary reconsideration, reversing the access gains
  • Payer backlash and coverage reversals: Employers and health plans facing rising GLP-1 drug spend may push back on PBM formulary decisions or impose utilization management restrictions (prior authorization, step therapy), limiting real-world access despite formal coverage
  • Macro and policy risk: Legislative or regulatory action targeting drug pricing (e.g., Medicare negotiation expansion) could structurally cap GLP-1 reimbursement rates, particularly given the high-profile cost debate around this drug class
  • NOVI Health partnership is geographically limited: The NVO–NOVI Health collaboration is currently focused on Singapore, limiting its near-term revenue impact and making it a modest rather than transformative driver for NVO's global top line

What to watch

  • Net price realization per GLP-1 script reported in LLY and NVO quarterly earnings — the key metric to determine whether volume gains are translating into revenue growth net of PBM rebates
  • Foundayo prescription volume and new-patient starts in the quarters following CVS Caremark formulary inclusion, as an early read on oral GLP-1 adoption rates
  • Additional PBM formulary decisions from Express Scripts and OptumRx — a cascade of coverage expansions would significantly amplify the bull case
  • GLP-1 discontinuation and refill rates from pharmacy data and real-world evidence studies, as a proxy for revenue durability
  • LLY and NVO obesity segment revenue guidance updates and any revisions to full-year outlooks following the CVS Caremark announcement
  • Competing oral GLP-1 or obesity drug approvals from rival pipelines that could fragment market share or accelerate pricing competition
  • Employer and health plan coverage trend data — whether large self-insured employers are adopting or restricting GLP-1 coverage will be a critical leading indicator for volume trajectory
  • Phase 3 readouts for expanded indications (metabolic disease, cardiovascular, NASH) that could broaden the approved use cases and justify further formulary expansion across therapeutic categories

Sources

  1. Lilly's Retevmo Cuts Lung Cancer Recurrence Risk in Phase 3 Trial 2026-06-01

    Positive late-stage trial results may support expanded therapeutic indications for GLP-1 class drugs.

  2. PBM Coverage Of Eli Lilly Obesity Drugs Reshapes Growth And Pricing Outlook 2026-06-02

    CVS Caremark covers Lilly's full obesity portfolio including oral Foundayo — major formulary win expanding patient access.

  3. Eli Lilly scores a first in major pharma milestone 2026-06-02

    Analysis confirms CVS coverage of Zepbound and Foundayo is a significant commercial inflection for LLY.

  4. NOVI Health Partners with Novo Nordisk to Expand Access to Structured Weight Care Support in Singapo 2026-06-02

    Novo Nordisk partners with NOVI Health to expand physician-led weight-loss program access, broadening NVO's commercial reach.

  5. Viking Therapeutics' Q3 Catalyst That Could Turn Eli Lilly's and Novo Nordisk's Daily Weight Loss Pi 2026-06-02

    Viking Therapeutics' Q3 Catalyst That Could Turn Eli Lilly's and Novo Nordisk's Daily Weight Loss Pill Strategy Upside Down

  6. Yahoo Finance 2026-06-02

    Eli Lilly and Company’s (LLY) Foundayo and Zepbound Set To Be Covered for Millions of Americans

  7. Yahoo Finance 2026-06-02

    Is Novo Nordisk A/S (NVO) Expanding Its Lead in Diabetes and Weight Loss Ahead of ADA Conference?

  8. Yahoo Finance 2026-06-02

    Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association (EHA) Annual Meeting

  9. Yahoo Finance 2026-06-02

    Beyond the AI Boom: 3 Forgotten Sectors to Buy Amid Historic Market Disconnect

  10. Yahoo Finance 2026-06-02

    M&A Is Back in a Big Way. These Are the Sectors in Play.

  11. ASCO26: Bispecific antibody and RET fusion-targeting assets garner attention in NSCLC 2026-06-03

    ASCO26: Bispecific antibody and RET fusion-targeting assets garner attention in NSCLC

  12. Yahoo Finance 2026-06-03

    Wegovy® pill launches in the UAE as Novo Nordisk expands global access to obesity care

  13. Yahoo Finance 2026-06-03

    Getting Alzheimer’s Drugs Into the Brain Is Hard. Now There’s a New Trick.

  14. Eli Lilly Just Proved Gene Editing Could Be Pharma's Next Gold Rush -- but CRISPR Therapeutics Inves 2026-06-03

    Eli Lilly Just Proved Gene Editing Could Be Pharma's Next Gold Rush -- but CRISPR Therapeutics Investors Should Watch Out

  15. Yahoo Finance 2026-06-03

    Novo Nordisk Expands Wegovy Pill Reach And Builds Global Obesity Care Model

  16. Why Is Novo Nordisk Stock Climbing Premarket Today? 2026-06-03

    Why Is Novo Nordisk Stock Climbing Premarket Today?

  17. Yahoo Finance 2026-06-03

    Ascidian and Lilly Enter Global Research Collaboration to Develop RNA Exon Editors for Devastating Kidney Diseases

  18. Novo Nordisk Expands Wegovy Rollout with Launch of Weight-Loss Pill in UAE (NVO) 2026-06-03

    Novo Nordisk Expands Wegovy Rollout with Launch of Weight-Loss Pill in UAE (NVO)

  19. Lilly, Ascidian link up in RNA exon editing pact 2026-06-03

    Lilly, Ascidian link up in RNA exon editing pact

  20. Is Bristol-Myers Squibb Stock Underperforming the Dow? 2026-06-03

    Is Bristol-Myers Squibb Stock Underperforming the Dow?

  21. Where Will Eli Lilly Stock be In 2028? 2026-06-03

    Where Will Eli Lilly Stock be In 2028?

  22. Yahoo Finance 2026-06-03

    Novo Nordisk is taking its Wegovy pill beyond the U.S.

  23. Yahoo Finance 2026-06-03

    European Stocks Close Lower; PMI Signals Possible Q2 Contraction

  24. Yahoo Finance 2026-06-03

    OCGN's Catalyst Calendar for Trial Data and Filings Through 2028

  25. Eli Lilly signs $1.9B gene-editing deal with Ascidian Therapeutics 2026-06-03

    Eli Lilly signs $1.9B gene-editing deal with Ascidian Therapeutics

  26. Novo Nordisk launches Wegovy pill in UAE, its first global market 2026-06-03

    Novo Nordisk launches Wegovy pill in UAE, its first global market

  27. Yahoo Finance 2026-06-03

    GeoVax CEO Highlights Renewed Strategic Interest in Vaccine Platforms and Infectious Disease Innovation

  28. NewLimit’s $435M megaround; Lilly’s busy dealmaking week 2026-06-03

    NewLimit’s $435M megaround; Lilly’s busy dealmaking week

  29. Yahoo Finance 2026-06-04

    Top Analyst Reports for Berkshire Hathaway, Eli Lilly & Walmart

  30. This Small-Cap Biotech Just Soared Over 160% — What Is The Novo Nordisk Connection? 2026-06-04

    This Small-Cap Biotech Just Soared Over 160% — What Is The Novo Nordisk Connection?

  31. Yahoo Finance 2026-06-04

    Eli Lilly, IBD Stock Of The Day, Flashes Two Buy Signals

  32. Veru Teams Up With Novo Nordisk for Obesity Combination Therapy Trial (VERU) 2026-06-04

    Veru Teams Up With Novo Nordisk for Obesity Combination Therapy Trial (VERU)

  33. Weight Watchers Expands Reach Through LillyDirect Partnership (WW) 2026-06-04

    Weight Watchers Expands Reach Through LillyDirect Partnership (WW)

  34. Eli Lilly Sees More Dealmaking Ahead as Management Looks To Leverage Its GLP-1 Success 2026-06-04

    Eli Lilly Sees More Dealmaking Ahead as Management Looks To Leverage Its GLP-1 Success

  35. Yahoo Finance 2026-06-04

    Eli Lilly Cuts Planned Germany Investment Amid Policy Concerns

  36. Yahoo Finance 2026-06-04

    Sesame Available via LillyDirect® Platform, Expanding Access to Affordable, Transparent Healthcare to Millions of Americans

  37. Yahoo Finance 2026-06-05

    Why WeightWatchers (WW) Stock Is Trading Up Today

  38. Yahoo Finance 2026-06-05

    Eli Lilly Pressure And RNA Expansion Reframe CRISPR Therapeutics Outlook

  39. Yahoo Finance 2026-06-05

    The Zacks Analyst Blog Highlights Berkshire, Eli Lilly, Walmart, Universal Health Realty Income and Utah

  40. HIMS Stock Slides Overnight: CEO Sees Healthcare Potential In Anthropic's AI Leap As Lilly, WeightWa 2026-06-05

    HIMS Stock Slides Overnight: CEO Sees Healthcare Potential In Anthropic's AI Leap As Lilly, WeightWatchers Turn Up The Heat

  41. Yahoo Finance 2026-06-05

    Novo Nordisk Tests Wegovy Combinations In Older Adults With Veru Trial

  42. Yahoo Finance 2026-06-05

    Jim Cramer Details How Eli Lilly Could Defeat Competitors

  43. Yahoo Finance 2026-06-05

    Forbion Expands Global Investment Leadership with Senior Promotions and Appointment of Operating Partner

  44. Yahoo Finance 2026-06-05

    Can Eli Lilly's 2026 Acquisition Spree Diversify Growth Beyond GLP-1s?

  45. Yahoo Finance 2026-06-05

    Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It

  46. Yahoo Finance 2026-06-05

    LLY Rises 14% in a Month: Should You Hold as Obesity Growth Continues?

  47. TD Cowen Raises GLP-1 Sales Forecast To $150B By 2030 – Industry Leaders LLY, NVO To Remain Dominant 2026-06-05

    TD Cowen Raises GLP-1 Sales Forecast To $150B By 2030 – Industry Leaders LLY, NVO To Remain Dominant

  48. Yahoo Finance 2026-06-05

    How Investors Are Reacting To Eli Lilly (LLY) Expanded GLP-1 Access And Digital Obesity Ecosystem

  49. GSK, Takeda and others notch key clinical wins in tough-to-treat diseases 2026-06-05

    GSK, Takeda and others notch key clinical wins in tough-to-treat diseases

  50. Yahoo Finance 2026-06-05

    UnitedHealth, Eli Lilly Lead Healthcare Rebound as Investors Seek Stability

  51. Yahoo Finance 2026-06-05

    Novo And Lilly Push Beyond US As Only 1%-2% Use Obesity Drugs Globally

  52. Yahoo Finance 2026-06-05

    GLP-1 Sales Forecast Jumps To $150 Billion By 2030

  53. Yahoo Finance 2026-06-05

    Here’s Why Eli Lilly (LLY) is Among the 10 Best American Stocks to Buy and Hold for the Next Decade

  54. Yahoo Finance 2026-06-05

    Novo Nordisk's investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes--presented at ADA 2026

  55. Yahoo Finance 2026-06-06

    Eli Lilly Broadens Beyond Obesity Drugs With Vaccine And Genetic Bets

  56. Novo's Wegovy Pill Isn't Just Beating Expectations -- It's Obliterating Them. Is the Beaten-Down Sto 2026-06-06

    Novo's Wegovy Pill Isn't Just Beating Expectations -- It's Obliterating Them. Is the Beaten-Down Stock a Buy Now?

  57. Yahoo Finance 2026-06-06

    People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than those who were switched t

  58. Yahoo Finance 2026-06-06

    Novo Nordisk Eyes Next GLP 1 Wave With Amycretin Trial Results

  59. Yahoo Finance 2026-06-06

    Jim Cramer Says Eli Lilly CEO Is a “Terrific Steward of His Shareholders’ Capital”

  60. Eli Lilly makes surprising retreat from major market 2026-06-06

    Eli Lilly makes surprising retreat from major market

  61. Yahoo Finance 2026-06-06

    Eli Lilly shares phase 3 data on triple agonist weight loss drug retatrutide

  62. Eli Lilly's $3.8 Billion Vaccine Bets: Here's the Big Story Many Investors Are Missing 2026-06-06

    Eli Lilly's $3.8 Billion Vaccine Bets: Here's the Big Story Many Investors Are Missing

  63. Yahoo Finance 2026-06-06

    Is It Too Late To Consider Eli Lilly (LLY) After Its 48% One-Year Surge?

  64. Yahoo Finance 2026-06-06

    Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and i

  65. Yahoo Finance 2026-06-06

    Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association's 2026 Scientific Sessions

  66. Pfizer’s Berobenatide GLP-1 Obesity Data Might Change The Case For Investing In Pfizer (PFE) 2026-06-06

    PFE presents Phase 2b results for berobenatide, a once-weekly/once-monthly GLP-1 receptor agonist.

  67. Tired of nausea or taking a GLP-1 pill every day? These experimental drugs could be better than Zepb 2026-06-06

    Independent commentary on a new wave of weight-loss therapies aiming to surpass existing GLP-1s.

  68. Yahoo Finance 2026-06-07

    Eli Lilly Expands Beyond Obesity With US$4b Vaccine And Genetic Bets

  69. Yahoo Finance 2026-06-07

    Wegovy® pill prescriptions surpass 3 million, 1 filled roughly every 5 seconds, bringing GLP-1 therapy to people with obesity previously untreated, while Novo Nordisk unveils new data at ADA 2026

  70. Yahoo Finance 2026-06-07

    Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause

  71. Related: Healthcare rotation as AI selloff hedge 2026-06-07

    Spillover from a related thesis (shares holding)

  72. AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH S 2026-06-07

    Amgen presents new diabetes/metabolic data at ADA 2026, intensifying competitive landscape in GLP-1 adjacent space.

  73. Wall Street sees huge upside as Novo Nordisk backs biotech company 2026-06-08

    Wall Street sees huge upside as Novo Nordisk backs biotech company

  74. Yahoo Finance 2026-06-08

    Q1 Earnings Review: Branded Pharmaceuticals Stocks Led by Eli Lilly (NYSE:LLY)

  75. Novo Nordisk shares retreat after ADA conference updates fail to excite investors (NVO) 2026-06-08

    Novo Nordisk shares retreat after ADA conference updates fail to excite investors (NVO)

  76. Yahoo Finance 2026-06-08

    Eli Lilly Obesity Wins Recast Retatrutide And Foundayo As Cardiometabolic Story

  77. Yahoo Finance 2026-06-08

    European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading

  78. Yahoo Finance 2026-06-08

    Novo Nordisk Real-World Data Supports Ozempic Against LLY's Mounjaro

  79. Yahoo Finance 2026-06-08

    Can Wegovy Pill's Rapid Uptake Give Novo Nordisk an Edge Over LLY?

  80. Yahoo Finance 2026-06-08

    Novo Nordisk Explores Wegovy Combination And Wider Semaglutide Benefits As Shares Fall

  81. Yahoo Finance 2026-06-08

    Eli Lilly Shares Rise Pre-Bell After Additional Retatrutide Data Shows Improvements in Obesity-Related Conditions

  82. LLY Stock Climbs As Oral GLP-1 Pill Beats Novo Nordisk, AstraZeneca’s Therapies In Diabetes Trials 2026-06-08

    LLY Stock Climbs As Oral GLP-1 Pill Beats Novo Nordisk, AstraZeneca’s Therapies In Diabetes Trials

  83. Yahoo Finance 2026-06-08

    Why Eli Lilly, In A Buy Zone, Is Still The 'Clear Winner' Of The 'Weight Loss Olympics'

  84. Yahoo Finance 2026-06-08

    Eli Lilly's Weight-Loss Pill Clears Its Toughest Hormonal Test Yet

  85. Yahoo Finance 2026-06-08

    Lilly Rises on Retatrutide Data

  86. Yahoo Finance 2026-06-08

    Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials

  87. Yahoo Finance 2026-06-08

    Novo Drops 3.2% As CEO Eyes Longevity And Aesthetics

  88. Yahoo Finance 2026-06-08

    Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other

  89. Yahoo Finance 2026-06-08

    ALT and the Rise of Dual Agonists Targeting Liver Disease

  90. Yahoo Finance 2026-06-08

    ALT Stock Guide to Pemvidutide's MASH, AUD and ALD Setup

  91. Yahoo Finance 2026-06-08

    Roche, Nurix Team Up to Advance BTK Degrader Bexobrutideg

  92. Yahoo Finance 2026-06-08

    Is Altimmune Worth Buying Ahead of 2026 Catalysts?

  93. Yahoo Finance 2026-06-09

    Why Eli Lilly (LLY) Stock Is Up Today

  94. Yahoo Finance 2026-06-09

    Convatec and Lilly Foundation Commit $5m to Partners In Health to Improve Care for Non‑communicable Disease and Chronic Conditions

  95. Yahoo Finance 2026-06-09

    Pentagon Accuses Alibaba, Baidu of Aiding China’s Military

  96. Yahoo Finance 2026-06-09

    AlzeCure Pharma Enters Into A Collaboration And Out-Licensing Agreement With Lilly For Alzheimer's Project

  97. Yahoo Finance 2026-06-09

    Can Eli Lilly's Clinical Momentum Keep the Stock at Record Highs?

  98. Yahoo Finance 2026-06-09

    Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway

  99. Stealthy startup Treeline plans a reverse merger 2026-06-09

    Stealthy startup Treeline plans a reverse merger

  100. Yahoo Finance 2026-06-09

    Novo Nordisk introduces updated Rybelsus® tablet formulation in Canada for adults living with type 2 diabetes

  101. Yahoo Finance 2026-06-09

    Eli Lilly Signs Alzheimer's Licensing Deal Worth Over $1 Billion With AlzeCure

  102. Yahoo Finance 2026-06-09

    Assessing Novo Nordisk (CPSE:NOVO B) Valuation As Share Price Weakness Follows A Tough Year

  103. Novo Nordisk puts AI at the centre of its clinical strategy 2026-06-09

    Novo Nordisk puts AI at the centre of its clinical strategy

  104. Yahoo Finance 2026-06-09

    Novo Wegovy Pill Tops 3M Prescriptions

  105. Yahoo Finance 2026-06-09

    Eli Lilly Expands Alzheimer’s Pipeline With AlzeCure Deal And Valuation Upside

  106. Yahoo Finance 2026-06-09

    Lilly Makes a New Alzheimer's Pipeline Move

  107. Yahoo Finance 2026-06-09

    2 Profitable Stocks for Long-Term Investors and 1 Facing Headwinds

  108. Yahoo Finance 2026-06-09

    Eli Lilly (LLY) Reports Positive Foundayo Weight Loss Data for Menopausal Women

  109. LLY’s EBGLYSS Gets FDA Nod For Every-8-Weeks Dosing, Cutting Treatment To Six Injections Per Year 2026-06-09

    LLY’s EBGLYSS Gets FDA Nod For Every-8-Weeks Dosing, Cutting Treatment To Six Injections Per Year

  110. Yahoo Finance 2026-06-09

    FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis

  111. Yahoo Finance 2026-06-10

    Is Eli Lilly and Company (LLY) One of the 10 Best Dividend Stocks to Buy According to D. E. Shaw?

  112. Yahoo Finance 2026-06-10

    Planisware unveils latest AI innovations at its annual Exchange26 EMEA conference

  113. Yahoo Finance 2026-06-10

    How The Eli Lilly (LLY) Investment Story Is Evolving With Recent Developments

  114. Yahoo Finance 2026-06-10

    Eli Lilly Wins FDA Nod for Extended Ebglyss Dosing in Eczema Care

  115. Yahoo Finance 2026-06-10

    Zepbound (tirzepatide) and Shaquille O'Neal launch national campaign after NBA legend learns the obstructive sleep apnea he has lived with for years is treatable

  116. Yahoo Finance 2026-06-10

    FDA Ebglyss Decision Adds New Thread To Eli Lilly Growth Story

  117. Yahoo Finance 2026-06-10

    European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading

  118. Eli Lilly continues dealmaking roll with $1bn AlzeCure agreement 2026-06-10

    Eli Lilly continues dealmaking roll with $1bn AlzeCure agreement

  119. Yahoo Finance 2026-06-11

    Novo Nordisk hit by cyber incident, probes data breach

  120. Yahoo Finance 2026-06-11

    Novo Nordisk A/S: IT Security incident at Novo Nordisk

  121. Yahoo Finance 2026-06-11

    Novo Nordisk: Wegovy® pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK

  122. Yahoo Finance 2026-06-11

    Novo Nordisk (NVO): Top 10 Large Cap Value Stocks to Buy Now

  123. Yahoo Finance 2026-06-11

    Abridge wants to be the operating system for medicine—and NVIDIA and Eli Lilly are helping build it

  124. NVO Stock Gains As UK Clears First Daily GLP-1 Weight-Loss Pill, Offsetting Security Breach News 2026-06-11

    NVO Stock Gains As UK Clears First Daily GLP-1 Weight-Loss Pill, Offsetting Security Breach News

  125. Yahoo Finance 2026-06-11

    Novo Nordisk Cybersecurity Breach Puts Data Controls And Investor Confidence In Focus

  126. Yahoo Finance 2026-06-11

    Novo Nordisk (NVO) Outpaces Stock Market Gains: What You Should Know

  127. Yahoo Finance 2026-06-12

    Eli Lilly and Company (LLY)’s Foundayo Hits New Weight Loss Milestone among Menopause Ladies

  128. Yahoo Finance 2026-06-12

    Oral Wegovy FDA Win Reframes Novo Nordisk Growth And Longevity Story

  129. Yahoo Finance 2026-06-12

    Novo Nordisk (NYSE:NVO) Stock Valuation Gap Questioned After Recent Share Price Pullback

  130. Yahoo Finance 2026-06-12

    Eli Lilly (LLY) Moves to Enforce 340B Claims Data Reporting Compliance

  131. Yahoo Finance 2026-06-12

    Goldman Sachs Maintains a Buy Rating on Eli Lilly (LLY), Cites Encouraging Obesity Treatment Pipeline — Eli Lilly and Company (NYSE:LLY) rose around 12% in May 2026, primarily driven by strong FQ1 2026 earnings beat and FDA approval for Foundayo and expansion of insurance coverage of obesity treatment.

  132. Yahoo Finance 2026-06-12

    Novo Nordisk Stock Up as UK Wegovy Pill Nod Eclipses Security Breach — NVO stock gains 3% as the United Kingdom becomes Europe's first country to approve the daily GLP-1 Wegovy weight-loss pill, overshadowing an IT security breach.

  133. Yahoo Finance 2026-06-12

    Update: Market Chatter: Some US Employers Plan to Drop GLP-1 Coverage for Obesity in 2027

  134. Yahoo Finance 2026-06-12

    Eli Lilly’s Abridge Bet Links Healthcare AI To Valuation And Growth

  135. UK gives Wegovy GLP-1 pill first European approval 2026-06-12

    UK gives Wegovy GLP-1 pill first European approval

  136. Abridge partners with Eli Lilly, Nvidia as AI scribe eyes expansion 2026-06-12

    Abridge partners with Eli Lilly, Nvidia as AI scribe eyes expansion

  137. Yahoo Finance 2026-06-12

    Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know — In the closing of the recent trading day, Eli Lilly (LLY) stood at $1, denoting a -2.41% move from the preceding trading day.

  138. Yahoo Finance 2026-06-13

    Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting

  139. Yahoo Finance 2026-06-13

    Jim Cramer Wasn’t Selling Eli Lilly (LLY)

  140. Yahoo Finance 2026-06-13

    Novo Nordisk (NVO) Reports Positive Phase 3 Reimagine Trial Results